These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8388602)

  • 21. Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease.
    Franco-Jarava C; Comas D; Orren A; Hernández-González M; Colobran R
    Clin Exp Immunol; 2017 Aug; 189(2):226-231. PubMed ID: 28369827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypically similar clones of serogroup B Neisseria meningitidis causing recurrent meningitis in a patient with total C5 deficiency.
    Chaudhuri AK; Banatvala N; Caugant DA; Fallon RJ; Whaley K
    J Infect; 1994 Sep; 29(2):236-8. PubMed ID: 7806892
    [No Abstract]   [Full Text] [Related]  

  • 23. Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report.
    Bae JY; Ham A; Choi HJ; Kim CJ
    Medicine (Baltimore); 2020 May; 99(21):e20362. PubMed ID: 32481330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
    Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
    Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.
    Andreoni J; Käyhty H; Densen P
    J Infect Dis; 1993 Jul; 168(1):227-31. PubMed ID: 8515116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity.
    Nicholson A; Lepow IH
    Science; 1979 Jul; 205(4403):298-9. PubMed ID: 451601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive Meningococcal Disease Unraveling a Novel Mutation in the C5 Gene in a Portuguese Family.
    Marujo F; Costa LC; Duarte R; Brito MJ; Cordeiro A; Neves C; Neves JF
    Pediatr Infect Dis J; 2019 Apr; 38(4):416-418. PubMed ID: 30882736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
    Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
    Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.
    Ross SC; Densen P
    Medicine (Baltimore); 1984 Sep; 63(5):243-73. PubMed ID: 6433145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
    Bröker M; Veitch K
    Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Mutations Causing C5 Deficiency in Three North-African Families.
    Colobran R; Franco-Jarava C; Martín-Nalda A; Baena N; Gabau E; Padilla N; de la Cruz X; Pujol-Borrell R; Comas D; Soler-Palacín P; Hernández-González M
    J Clin Immunol; 2016 May; 36(4):388-96. PubMed ID: 27026170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expecting the unexpected: Complement screening in the meningococcal vaccination era.
    Wong PH; Lee RU
    J Allergy Clin Immunol Pract; 2019; 7(6):2076-2077. PubMed ID: 30797079
    [No Abstract]   [Full Text] [Related]  

  • 35. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.
    Platonov AE; Vershinina IV; Kuijper EJ; Borrow R; Käyhty H
    Vaccine; 2003 Oct; 21(27-30):4437-47. PubMed ID: 14505927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hereditary complement C5 deficiency: study of 3 Tunisian adult cases and literature review].
    Zerzri Y; Kallel-Sellami M; Abdelmalek R; Laadhar L; Ben Chaabane T; Makni S
    Tunis Med; 2010 Apr; 88(4):269-76. PubMed ID: 20446263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of meningococcal meningitis with meningococcal vaccines.
    Artenstein MS
    Yale J Biol Med; 1975 Jul; 48(3):197-200. PubMed ID: 808913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.